Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

F-star’s FS118 Development Program To Include Checkpoint Naïve Cancer Patients

F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.  The new study will…
byVandana Singh
August 12, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients. 
  • The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL). 
  • FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
  • In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs. 
  • F-Star ended the quarter with cash and cash equivalents of $81.6 million.
  • Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Preview: American Vanguard’s Earnings

By Benzinga Insights
Today, 8:13 AM
American Vanguard (NYSE:AVD) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that American Vanguard will likely report an Earnings Per Share (EPS) of $0.14

AVD

Read More

Cannabis Movers & Shakers: Former Anti-Marijuana Congressman Joins Georgia-Based Medical Marijuana Co. And Flowr Corp, Pet Releaf, MariMed, Veritas Fine Cannabis, Flower One, Goodness Growth Each Announce Appointments

By Jelena Martinovic
Today, 8:13 AM
The Flowr Corp. Taps Ryan Roebuck To Serve On The Board Cannabis company The Flowr Corporation (TSX: FLWR) (OTC: FLWPF) announced recently that Ryan Roebuck will join its board of directors.

CSE:FFNT